IbiayiDagogo-JackMD

PubMed

• A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
  Riely, G., Smit, E., Ahn, M., Felip, E., Ramalingam, S., Tsao, A., Johnson, M., Gelsomino, F., Esper, R., Nadal, E., Offin, M., Provencio, M., Clarke, J., Hussein, M.,...> ;Future Oncology. 2024 Feb 15
• We Don't Talk (Enough) About BRAF.
  Ibiayi Dagogo-Jack> ;Journal of Thoracic Oncology. 2023 Nov 1
• Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.
  Ibiayi Dagogo-Jack, Lesli A Kiedrowski, Jochen K Lennerz> ;Lung Cancer. 2023 Dec 1
• 1 citations
  Targeted Approaches to Treatment of Pleural Mesothelioma: A Review.
  Ibiayi Dagogo-Jack> ;JCO Precision Oncology. 2023 Sep 1
• Extrathoracic Metastases in Pleural Mesothelioma.
  Ibiayi Dagogo-Jack, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy> ;JTO Clinical and Research Reports. 2023 Sep 1
• 3 citations
  Efficacy and Tolerability of/Combinations in Patients With-Rearranged Lung Cancer With AcquiredAmplification: A Retrospective Analysis.
  Ibiayi Dagogo-Jack, Lesli A Kiedrowski, Rebecca S Heist, Jessica J Lin, Catherine B Meador, Elizabeth A Krueger, Andrew Do, Jennifer Peterson, Lecia V Sequist, Justin ...> ;JTO Clinical and Research Reports. 2023 Aug 1
• 1 citations
  Integrated Radiology, Pathology, and Pharmacy Program to Accelerate Access to Osimertinib.
  Ibiayi Dagogo-Jack, Amanda Manoogian, Nicholas Jessop, N Zeke Georgantas, Florian J Fintelmann, Alexander Farahani, Subba R Digumarthy, Melissa C Price, Erik E Folch, ...> ;JCO Oncology Practice. 2023 Sep 1
• 1 citations
  B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma.
  Ibiayi Dagogo-Jack, Ivan Valiev, Nikita Kotlov, Anna Belozerova, Aleksandra Lopareva, Anna Butusova, Naira Samarina, Alexandra Boyko, Zhongmin Xiang, Monique Johnson, ...> ;JTO Clinical and Research Reports. 2023 Jul 1
• 7 citations
  Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With-Mutant Metastatic Non-Small-Cell Lung Cancer.
  Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Micha...> ;Journal of Clinical Oncology. 2023 Jul 20
• B cell-dependent subtypes and treatment-based immune correlates to survival in stage 3 and 4 lung adenocarcinomas.
  Susan Raju Paul, Ivan Valiev, Skylar E Korek, Vladimir Zyrin, Diana Shamsutdinova, Olga Gancharova, Alexander Zaitsev, Ekaterina Nuzhdina, Diane L Davies, Ibiayi Dagog...> ;FASEB Bioadvances. 2023 Apr 1
• 1 citations
  Primary Resistance to Larotrectinib in a Patient With Squamous NSCLC With SubclonalFusion: Case Report.
  Mary C Boulanger, Jennifer S Temel, Mari Mino-Kenudson, Lauren L Ritterhouse, Ibiayi Dagogo-Jack> ;JTO Clinical and Research Reports. 2023 Apr 1
• Reply to the Letter to the Editor From Zhao et al.
  Ibiayi Dagogo-Jack, Stan Krulewicz, Beow Y Yeap> ;Journal of Thoracic Oncology. 2023 Mar 1
• 2 citations
  Management of Lung Cancer in the Patient with Interstitial Lung Disease.
  Angela J Frank, Ibiayi Dagogo-Jack, Ioana A Dobre, Sarah Tait, Lana Schumacher, Florian J Fintelmann, Leah M Fingerman, Florence K Keane, Sydney B Montesi> ;The Oncologist. 2023 Jan 18
• 9 citations
  Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
  Ibiayi Dagogo-Jack, Antonello Abbattista, Stan Krulewicz, Andrew Do, Jennifer Peterson, Jessica J Lin, Justin F Gainor, Rossella Messina, Elizabeth A Krueger, Holger T...> ;Journal of Thoracic Oncology. 2023 Jan 1
• 4 citations
  Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network.
  Dora Dias-Santagata, Rebecca S Heist, Adam Z Bard, Annacarolina F L da Silva, Ibiayi Dagogo-Jack, Valentina Nardi, Lauren L Ritterhouse, Laura M Spring, Nicholas Jesso...> ;The Oncologist. 2022 Nov 3
• 1 citations
  There Is No Unmet Need for Another Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Inhibitor for Metastatic NSCLC.
  Ibiayi Dagogo-Jack, Zofia Piotrowska> ;Journal of Thoracic Oncology. 2022 Oct 1
• 3 citations
  Clinicopathologic Characteristics and Outcomes for Patients WithG12D-Mutant NSCLC.
  Alona Muzikansky, Jochen Lennerz, Farhaana Narinesingh, Mari Mino-Kenudson, Yin P Hung, Zofia Piotrowska, Ibiayi Dagogo-Jack, Lecia V Sequist, Justin F Gainor, Jessica...> ;JTO Clinical and Research Reports. 2022 Sep 1
• 15 citations
  Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
  Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A Nebhan, Ibiayi Dagogo-Jack, Nathaniel J Myall, Georg Richtig, Jillian W P Bracht, Marco Gerlinge...> ;JCO Precision Oncology. 2022 Aug 1
• 10 citations
  Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
  Ibiayi Dagogo-Jack, Russell W Madison, Jochen K Lennerz, Kuei-Ting Chen, Julia F Hopkins, Alexa B Schrock, Lauren L Ritterhouse, Ashley Lester, Keith A Wharton Jr, Mar...> ;JCO Precision Oncology. 2022 Jun 1
• 20 citations
  Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
  Aya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, Mari Mino-Kenudson, Theodore R Johnson, Ping Wei, Scott L Weinrich, Michele A McTigue, Makeba A Walcott, Linh Nguye...> ;Nature Cancer. 2022 Jun 1
• 9 citations
  Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.
  Ibiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist, Subba R Digumarthy, Jessica J Lin, Justin F Gainor, Michael S Rabin, Rebecca S Heist, Alona Muzikansky, Alic...> ;JCO Precision Oncology. 2022 May 1
• 36 citations
  Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.
  Priscilla K. Brastianos, Matthew R. Strickland, Eudocia Q. Lee, Nancy Wang, Justine V. Cohen, Ugonma Chukwueke, Deborah Forst, April F. Eichler, Beth Overmoyer, Nan Li...> ;Nature Communications. 2021 Oct 12
• 2 citations
  Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer-A Likely Limited Role on a Deep Bench.
  Ibiayi Dagogo-Jack> ;JAMA Oncology. 2021 Nov 1
• 7 citations
  Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
  Lindsey Mortensen, Zehra Ordulu, Ibiayi Dagogo-Jack, Veerle Bossuyt, Loren Winters, Alphonse G. Taghian, Barbara L. Smith, Leif W. Ellisen, Lesli A. Kiedrowski, Jochen...> ;The Oncologist. 2021 Oct 1
• 49 citations
  Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer
  Jessica J. Lin, Noura J. Choudhury, Satoshi Yoda, Viola W. Zhu, Ted William Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Charlotte E. Lee, Andre...> ;Clinical Cancer Research. 2021 May 15
• Join now to see all

Lectures

• Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors. 
  2019 ASCO Annual Meeting - 6/1/2019
• Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC). 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018